

Macrophages play a leading role in determining the direction of astrocytic migration in spinal cord injury via ADP-P2Y1R axis

小野, 玄太郎

<https://hdl.handle.net/2324/7182348>

出版情報 : Kyushu University, 2023, 博士 (医学) , 課程博士
バージョン :
権利関係 : © The Author(s) 2023





OPEN Macrophages play a leading role in determining the direction of astrocytic migration in spinal cord injury via ADP-P2Y1R axis

Gentaro Ono¹, Kazu Kobayakawa^{1✉}, Hirokazu Saiwai¹, Tetsuya Tamaru¹, Hirotaka Iura¹, Yohei Haruta¹, Kazuki Kitade¹, Keiichiro Iida¹, Kenichi Kawaguchi¹, Yoshihiro Matsumoto¹, Makoto Tsuda^{2,3}, Tomohiko Tamura⁴, Keiko Ozato⁵, Kazuhide Inoue^{3,6}, Dai-Jiro Konno⁷, Takeshi Maeda⁸, Seiji Okada⁹ & Yasuharu Nakashima¹

After spinal cord injury (SCI), inflammatory cells such as macrophages infiltrate the injured area, and astrocytes migrate, forming a glial scar around macrophages. The glial scar inhibits axonal regeneration, resulting in significant permanent disability. However, the mechanism through which glial scar-forming astrocytes migrate to the injury site has not been clarified. Here we show that migrating macrophages attract reactive astrocytes toward the center of the lesion after SCI. Chimeric mice with bone marrow lacking *IRF8*, which controls macrophage centripetal migration after SCI, showed widely scattered macrophages in the injured spinal cord with the formation of a huge glial scar around the macrophages. To determine whether astrocytes or macrophages play a leading role in determining the directions of migration, we generated chimeric mice with reactive astrocyte-specific *Socs3*^{-/-} mice, which showed enhanced astrocyte migration, and bone marrow from *IRF8*^{-/-} mice. In this mouse model, macrophages were widely scattered, and a huge glial scar was formed around the macrophages as in wild-type mice that were transplanted with *IRF8*^{-/-} bone marrow. In addition, we revealed that macrophage-secreted ATP-derived ADP attracts astrocytes via the P2Y1 receptor. Our findings revealed a mechanism through which migrating macrophages attract astrocytes and affect the pathophysiology and outcome after SCI.

Abbreviations

SCI	Spinal cord injury
<i>IRF8</i>	Interferon Regulatory Factor 8
IL-1 α	Interleukin-1 α
IL-1 β	Interleukin-1 β
IL-6	Interleukin-6
TNF- α	Tumor necrosis factor- α
ATP	Adenosine triphosphate
ADP	Adenosine diphosphate

¹Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ²Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ³Kyushu University Institute for Advanced Study, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka-shi, Fukuoka 819-0395, Japan. ⁴Department of Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. ⁵Program in Genomics of Differentiation, Section on Molecular Genetics of Immunity, Division of Developmental Biology, NICHD, National Institutes of Health, Building 6A, Room 2A01, 6 Center Drive, Bethesda, MD 20892, USA. ⁶Greenpharma Research Center for System Drug Discovery, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ⁷Department of Energy and Materials, Faculty of Science and Engineering, Kindai University, Osaka 577-8502, Japan. ⁸Department of Orthopaedic Surgery, Spinal Injuries Center, 550-4 Igisu, Iizuka, Fukuoka 820-8508, Japan. ⁹Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. ✉email: kobayakawa.kazu.000@m.kyushu-u.ac.jp

WT	Wild type
Nes	Nestin
Socs3	Suppressor of cytokine signaling-3
EGFP	Enhanced green fluorescent protein
DMEM	Dulbecco's Modified Eagle Medium
RPMI1640	Roswell Park Memorial Institute medium 1640
EDTA	Ethylenediaminetetraacetic acid
GFAP	Glial fibrillary acidic protein
CD68	Cluster of Differentiation 68
<i>Slc39a6</i>	Solute Carrier Family 39 Member 6
MAPK	Mitogen-activated protein kinase
ERK	Extracellular signal-regulated kinase
<i>Stat3</i>	Signal transducer and activator of transcription 3

Although spinal cord injury (SCI) causes severe disability, effective treatments have not been established¹. When the blood-spinal cord barrier is disrupted by mechanical injury, inflammatory cells, such as neutrophils and macrophages, infiltrate into the spinal cord, and these cells secrete inflammatory cytokines, such as interleukin (IL)-1 α , IL-1 β , IL-6, and tumor necrosis factor (TNF)- α , causing secondary damage². The influx of inflammatory cells activates resident glia, including astrocytes, and remodels the extracellular matrix with an increase in fibronectin, collagen, and laminin³. The extracellular matrix and inflammatory cells are located at the center of the injury, and astrocytes migrate toward them to form a glial scar that serves as a physical barrier. Since this barrier prevents axonal regeneration, elucidation of the mechanism of glial scar formation is critical for developing new treatments for SCI.

We previously reported that Stat3 regulates astrocyte migration⁴. However, the factors that attract astrocytes to the injury site remain unknown, although astrocyte migration is one of the most important processes in glial scar formation. In this study, we attempted to identify factors that attract astrocytes to the injury center by focusing on macrophages inside the glial scar. The proportion of macrophages at the injury center varies over time. Especially after the subacute stage, when the glial scar is formed, the infiltration of macrophages is particularly pronounced (7 days post-injury)⁵, suggesting that macrophages may also be involved in the formation of the glial scar. We hypothesized that macrophages might also be involved in the appearance of glial scars. We reported that in *IRF8*^{-/-} mice, in which macrophages are widely scattered after SCI due to impaired migration with the downregulated expression of purinergic receptors, larger glial scars were formed in comparison to wild-type (WT) mice⁶. In the central nervous system (CNS), astrocytes form close intercellular communication with other cell types, such as neurons and microglia, in which purine receptors play a significant role, for example, in regulating homeostasis, with consequences for synaptic transmission, and higher-order cognitive processes^{7,8}. In addition, macrophages have been shown to attract other macrophages by secreting ATP, the ligand for the purine receptor⁹. Therefore, we hypothesized that macrophages also induce astrocytes via purine receptors. In this study, we demonstrated the effect of macrophages on astrocyte migration after SCI, which is critical for glial scar formation.

Results

Macrophages attract astrocytes in SCI. After SCI, macrophages infiltrate into the injury site and migrate toward the epicenter with a shift in reactive astrocyte distribution toward the peri-injury area^{4,6}. Initially, the distribution of scattered macrophages and astrocytes shifts toward the epicenter over time as well, but eventually, they are located in different sites, with macrophages and microglia in the center of the lesion and astrocytes at the margin of the injury (Fig. 1a,b). These results suggest that macrophage migration may affect the shift in astrocyte distribution. To investigate what happens to astrocytes when macrophage migration is impaired, a bone marrow chimera mouse model was created by transplanting bone marrow from *IRF8*^{-/-} mice (which have been reported to show impaired macrophage migration⁶) into *Nes-Cre-EGFP* mice, which showed the expression of EGFP in reactive astrocytes (Supplementary Fig. S1a,b). Thus, in this chimeric mouse, the function of astrocytes was normal, and only macrophages showed an impaired migration ability due to the knockout of *IRF8*. Using the chimeric mouse models, we compared the scar area at 7 and 14 days after SCI and found that the glial scar area in mice with impaired macrophage migration was significantly greater than that in mice with normal macrophage migration at both time points (Fig. 2a,b). These results suggest that the migration of macrophages influences the shift in reactive astrocyte distribution and subsequent astrocytic scar formation. In addition, we investigated whether the intrinsic nature of astrocytes was altered with impairment of macrophage migration. First, since astrocytes are known to overlap processes at the edge of the injury area, resulting in scar formation, we evaluated the effect on overlapping processes via cell density. We found no significant difference in cell density at either 7 or 14 days post-injury, indicating that loss of *IRF8* in macrophages had no significant effect on the overlapping of processes by astrocytes (Fig. 2c–h). Next, since activated astrocytes are hypertrophied, we investigated whether astrocyte activity was affected by assessing the area of astrocyte cell bodies. As a result, the area of EGFP⁺ astrocytes was not altered by impaired macrophage migration, suggesting that impaired macrophage migration had no significant effect on the overlapping of processes by astrocytes (Fig. 2c–h). Finally, the proliferative capacity of astrocytes was evaluated by Ki67 staining. No significant differences were found in proliferation between astrocytes in these two chimeric mice (Fig. 2c–h). These findings suggest that macrophages attract astrocytes extrinsically without altering their proliferative potential. We previously reported that *Slc39a6* is involved in the Stat3-mediated migration mechanism of reactive astrocytes⁴. Therefore, we assessed the expression of *Slc39a6* and found no significant difference (Fig. 2i). This result suggests that




Figure 1. Temporal changes in macrophages and astrocytes in SCI. (a) Macrophage migration occurred after SCI, followed by glial scar formation by astrocytes at 7–14 days post-injury (dpi). Scale bar: 500 μ m. (b) Quantitative analysis of the craniocaudal range of astrocytes in the glial scar and macrophages (n = 6 per group). Error bars indicate the SEM.

the attraction of astrocytes by macrophages is not mediated by Stat3 in astrocytes. These findings indicate that IRF8-mediated macrophage migration affects the shift in reactive astrocyte distribution without changing the proliferation, activation, or Stat3-mediated migration capacity of reactive astrocytes.


Macrophage migration is the leading factor in SCI. Socs3 is a negative regulator of Stat3, which is involved in the expression of intermediate filaments, cell proliferation, and cytoskeletal changes¹⁰. Regarding the direct involvement between astrocytic migration and these functions, it has only been reported that migration is regulated by changes in the cytoskeleton via RhoA¹¹. In fact, we previously reported that astrocyte migration is enhanced and that the rapid migration of reactive astrocytes leads to the early accumulation of macrophages in *Nes-Socs3^{-/-}EGFP⁺* mice, in which the *Socs3* gene in reactive astrocytes was deleted⁴. In contrast, the poor migration of *IRF8^{-/-}* macrophages was accompanied by the widespread distribution of reactive astrocytes (Fig. 2a,b). These facts suggest the possibility of an interaction between infiltrating blood-derived macrophages and reactive astrocytes after SCI. To further investigate whether the migration of *IRF8^{-/-}* macrophages could affect the shift in reactive astrocyte distribution, we generated two additional chimeric mice: [macrophages; *IRF8^{+/+}*]/[reactive astrocytes; *Nes-Socs3^{-/-}EGFP⁺*] and [macrophages; *IRF8^{-/-}*]/[reactive astrocytes; *Nes-Socs3^{-/-}EGFP⁺*] using EGFP-negative *IRF8^{+/+}* or *IRF8^{-/-}* bone marrow cells with *Nes-Socs3^{-/-}EGFP⁺* recipient mice (Fig. 3a). In the former chimeric mice, both *IRF8^{+/+}* macrophages and *Nes-Socs3^{-/-}* reactive astrocytes showed a narrow distribution after SCI, as described in our previous study (Fig. 3b–d)⁴. However, even with *Nes-Socs3^{-/-}EGFP⁺* reactive astrocytes, the migration disorder of *IRF8^{-/-}* macrophages was not rescued in the latter chimeric mice (Fig. 3b–d). Instead, the *Nes-Socs3^{-/-}EGFP⁺* reactive astrocytes with *IRF8^{-/-}* macrophages were more widely distributed than those with *IRF8^{+/+}* macrophages (Fig. 3b,d). These results may indicate that while the migration of macrophages and reactive astrocytes interact with one another, the migration of macrophages is more strongly affected by macrophage IRF8 than by the enhancement of reactive astrocyte migration. We further examined the interaction between the migration of macrophages and reactive astrocytes on functional recovery after SCI. There was no significant difference among WT, *IRF8^{-/-}* and these chimeric mice before SCI or at 1 day post-injury (Fig. 3e). However, at 14 days post-injury, although the former chimeric mice with WT macrophages and *Nes-Socs3^{-/-}* reactive astrocytes showed significantly ameliorated functional recovery in comparison to WT

Figure 2. Inhibition of macrophage migration results in larger glial scars. **(a)** Change in the distribution of EGFP⁺ reactive astrocytes over time in the injured spinal cord of [reactive astrocytes: *Nes-Cre-EGFP*⁺/macrophages: WT] and [reactive astrocytes: *Nes-Cre-EGFP*⁺/macrophages: *IRF8*^{-/-}] mice. Reactive astrocytes: *Nes-Cre-EGFP*⁺/macrophages: *IRF8*^{-/-} mice had larger glial scars. Scale bar: 500 μ m. **(b)** Quantitative analysis of the area surrounded by EGFP-positive cells: reactive astrocytes. There were significant differences between [reactive astrocytes: *Nes-Cre-Socs3*^{-/-}*EGFP*⁺/macrophages: WT] and [reactive astrocytes: *Nes-Cre-Socs3*^{-/-}*EGFP*⁺/macrophages: *IRF8*^{-/-}] mice at 7 days and 14 dpi (n = 6 per group at each time point). **(c)** High-magnification view of WT bone chimeric mice at 1 week after injury. Scale bar: 100 μ m. **(d)** High-magnification view of *IRF8*^{-/-} bone chimeric mice at 1 week after injury. Scale bar: 100 μ m. **(e)** High-magnification view of WT bone chimeric mice at 2 weeks after injury. Scale bar: 100 μ m. **(f)** High-magnification view of *IRF8*^{-/-} bone chimeric mice 2 weeks after injury. Scale bar: 100 μ m. **(g)** Quantitative analysis of the number of reactive astrocytes, the area of astrocyte cell bodies, and a proliferation assessment by Ki67 staining at 7 dpi. No significant differences were found in any of the parameters (n = 6 per group). **(h)** Quantitative analysis of the number of reactive astrocytes, the area of astrocyte cell bodies, and a proliferation assessment by Ki67 staining at 14 dpi. No significant differences were found in any of the parameters (n = 6 per group). **(i)** The time course of *Slc39a6* expression in the injured spinal cord determined by real-time RT-PCR in [reactive astrocytes: *Nes-Cre-Socs3*^{-/-}*EGFP*⁺/macrophages: WT] and [reactive astrocytes: *Nes-Cre-Socs3*^{-/-}*EGFP*⁺/macrophages: *IRF8*^{-/-}] mice (n = 6 per group at each time point). Each group was normalized to *Gapdh* values. There were no significant differences between [reactive astrocytes: *Nes-Cre-Socs3*^{-/-}*EGFP*⁺/macrophages: WT] and [reactive astrocytes: *Nes-Cre-Socs3*^{-/-}*EGFP*⁺/macrophages: *IRF8*^{-/-}] mice. **p* < 0.05, unpaired t-test. Error bars indicate the SEM.

mice, the latter chimeric mice with *IRF8*^{-/-} macrophages and *Nes-Socs3*^{-/-} reactive astrocytes exhibited greater deterioration of motor functional recovery in comparison to WT and the former chimeric mice (Fig. 3e). These findings revealed that for motor recovery after SCI, the loss of autonomous macrophage migration due to *IRF8* knockout has a greater impact than the enhancement of reactive astrocyte migration. Regarding their interaction, these findings clarified that macrophage migration plays a leading role in determining their distribution. In addition, *Socs3* is a negative feedback factor for *Stat3*^{12,13}, and it is known that *Stat3* regulates reactive astrocyte migration via the Rho A small G protein¹¹. In this study, the loss of *IRF8* in macrophages also altered the astrocyte distribution with or without the expression of *Socs3*. This result also supports the hypothesis that the pathway by which macrophages attract astrocytes is not mediated by *Stat3* (Fig. 2i).

Macrophage-astrocyte interactions via P2Y1 receptors. To elucidate how macrophages affect the migration of astrocytes, we focused on the P2Y1 receptor (P2Y1R) as a representative receptor in the migration pathways, because P2Y1R was reported to be involved in astrocyte velocity in traumatic brain injury¹⁴ and to regulate cell migration via the ADP-P2Y1R-MAP/ERK pathway¹⁵. Therefore, we hypothesized that ATP-derived ADP secreted by macrophages might attract astrocytes via P2Y1R. First, we performed immunostaining to confirm the expression of P2Y1R in the astrocytes of the injured spinal cord. As a result, P2Y1R was expressed in astrocytes in vitro (Fig. 4a). Second, we performed a transwell assay using primary cultured astrocytes. To investigate whether macrophages attract astrocytes, we cocultured the cells with macrophages (Fig. 4b). Coculture with macrophages significantly increased the number of migrating astrocytes (Fig. 4c,d). Next, we performed three experiments to clarify the pathway by which macrophages attract astrocytes (Fig. 4e). First, we evaluated whether ADP attracts astrocytes. The number of migrating astrocytes was significantly increased when a medium with ADP was used, indicating that ADP attracts astrocytes (Fig. 4f,g). Second, to confirm whether the attraction of astrocytes by macrophages was due to the secretion of ADP, we performed coculturing of macrophages and astrocytes with apyrase, an enzyme that degrades ADP (Fig. 4e). The results showed that the number of migrating astrocytes did not increase in the presence of apyrase, indicating that astrocyte migration is regulated by macrophage-derived ADP (Fig. 4f,g). Finally, to determine whether P2Y1R is the receptor on astrocytes on which ADP acts, we cocultured astrocytes and macrophages with MRS-2179, an antagonist of P2Y1R. With MRS-2179, the number of migrating astrocytes did not increase, indicating that astrocytes are attracted to macrophages by the ADP-P2Y1R pathway (Fig. 4f,g). Since ATP secreted from macrophages is degraded to ADP, macrophages attract astrocytes via the ADP-P2Y1R axis, resulting in a shift in astrocyte distribution toward macrophages in the epicenter and astrogial scar formation after SCI.

Injection of ADP attracts astrocytes to the center of the injured spinal cord. Although P2Y1R could be expressed in many cell types, the majority of P2Y1R-positive cells were astrocytes in the injured area of the spinal cord (Fig. 5a,b). Therefore, we evaluated the administration of ADP to *IRF8*^{-/-} mice, which are known to exhibit extensive macrophage migration after SCI, could shift astrocyte distribution via the ADP-P2Y1R pathway. As ADP is known to be degraded in vivo in a short time, we devised a method of continuous intraspinal injection (Fig. 5c). The continuous intraspinal injection of ADP attracted astrocytes to the center of the SCI and reduced the glial scar area in comparison to controls, which were *IRF8*^{-/-} mice treated with PBS (Fig. 5d,e). Next, WT mice were injected with MRS-2179, a P2Y1R antagonist, into the spinal cord during the subacute phase of SCI. In contrast, in mice injected with MRS-2179, astrocytes were not attracted to the center of the injury, and glial scars were enlarged (Fig. 5e,f).






Figure 3. Impaired macrophage migration disturbs migration of genetically promoted migration of astrocytes after SCI. **(a)** A schematic illustration of the creation of bone marrow chimeric mice. **(b)** Immunostaining of the injured spinal cord in [reactive astrocytes: *Nes-Cre-Soc3^{-/-}-EGFP⁺*/macrophages: WT] and [reactive astrocytes: *Nes-Cre-Soc3^{-/-}-EGFP⁺*/macrophages: *IRF8^{-/-}*] mice. Scale bar: 500 μ m. **(c)** Quantitative analysis of the extent of macrophage migration. The lack of *Socs3* in reactive astrocytes narrows the range of macrophage migration, while the lack of *IRF8* widens the range of macrophage migration ($n=6$ per group). **(d)** Quantitative analysis of the area surrounded by EGFP-positive cells: reactive astrocytes. There were significant differences in the area between [reactive astrocytes: *Nes-Cre-Soc3^{-/-}-EGFP⁺*/macrophages: WT] and [reactive astrocytes: *Nes-Cre-Soc3^{-/-}-EGFP⁺*/macrophages: *IRF8^{-/-}*] mice at 7 days post-injury ($n=6$ per group). **(e)** The time course of motor function score after SCI. Significant differences were only seen at 14 dpi ($n=6$ per group). * $p<0.05$, ordinary one-way ANOVA/two-way ANOVA. Error bars indicate the SEM.

Discussion

In this study, we showed that macrophages are essential for the shift in astrocyte distribution after SCI using bone marrow chimeric mice. Impairment of macrophage migration led to the widespread distribution of reactive astrocytes. *Socs3^{-/-}* astrocytes, the migration of which is usually promoted and which usually show a narrow distribution, showed widespread distribution with impaired macrophage migration.




Figure 4. Macrophages attract astrocytes via the P2Y1R. **(a)** The expression of P2Y1R in astrocytes in vitro. Scale bar: 10 μ m. **(b)** A schematic illustration of the astrocyte transwell assay with/without macrophages. **(c)** Transwell assay of astrocytes in the control and macrophage groups. Diff-Quik staining images are representative of 2 independent experiments. Scale bar: 100 μ m. **(d)** Comparison of the number of migrating cells in the control and macrophage groups (9 sections/3 wells per group). **(e)** A schematic illustration of the transwell assay to reveal the pathways by which macrophages attract astrocytes. **(f)** Transwell assay of astrocytes in the control and macrophage groups. Diff-Quik staining images are representative of 3 independent experiments. Scale bar: 100 μ m. **(g)** Comparison of the number of migrating cells between macrophages, without macrophages/with ADP, with macrophages/with apyrase, and with macrophages/with MRS-2179 (9 sections/3 wells per group). * $p < 0.05$, ordinary one-way ANOVA/unpaired t-test. Error bars indicate the SEM.




Figure 5. ADP attracts astrocytes in vivo. **(a)** Immunostaining of the injured spinal cord at 7 dpi. Scale bar: 50 μ m. **(b)** The quantitative analysis of composition in P2Y1R⁺ cells. There was a significant difference between the GFAP⁺ cells and GFAP⁻ cells. White arrowheads are P2Y1R⁺/GFAP⁺ cells, hollow arrowhead is P2Y1R⁺/GFAP⁻ cell. Scale bar: 50 μ m. **(c)** A schematic illustration of continuous intraspinal injection of ADP. **(d)** Immunostaining of the injured spinal cord in the ADP continuous intraspinal injection group and the control group. Scale bar: 500 μ m. **(e)** The quantitative analysis of the area surrounded by GFAP-positive cells. There was a significant difference between the ADP continuous intraspinal injection group and the control group ($n = 6$ per group). **(f)** Immunostaining of the injured spinal cord in the MRS-2179 intraspinal injection group and the PBS intraspinal injection group. Scale bar: 500 μ m. **(g)** The quantitative analysis of the area surrounded by GFAP-positive cells. There was a significant difference between the MRS-2179 intraspinal injection group and the PBS intraspinal injection group ($n = 6$ per group). * $p < 0.05$, unpaired t-test. Error bars indicate the SEM.

These results indicate that macrophages play a leading role over astrocytes in the cell migration of macrophages and astrocytes after SCI. In addition, the coculture of macrophages and astrocytes also showed that macrophages attract astrocytes. Using antagonists, we further elucidated that ADP derived from ATP secreted extracellularly by macrophages attracted astrocytes via P2Y₁R. Furthermore, in vivo, the continuous administration of ADP to the center of the injury attracts astrocytes to the center of the injury and reduces the area of the glial scar. These findings indicated that macrophages affect the shift in reactive astrocyte distribution and are important clues to clarifying the pathophysiology of SCI.

Since the mechanisms of glial scar formation are quite complex, we divided glial scar formation into the following stages and focused on each stage: change from naïve astrocytes to reactive astrocytes, astrocytic migration to the injured area, and change from reactive astrocytes to scar-forming astrocytes. Regarding the migration of astrocytes to the injured area, we previously reported that astrocyte migration involves Stat3 and its negative regulator, Socs3, and that the knockout of *Stat3* impedes astrocyte migration^{4,11}. Therefore, we initially suspected the involvement of Socs3 in the mechanism through which macrophages attract astrocytes. However, the results of this study showed that Socs3 is not involved in the mechanism through which macrophages attract astrocytes. Therefore, we focused on the P2Y receptor, which has been reported to be involved in multiple cell-to-cell communication pathways in the CNS. For example, microglia, neurons, and astrocytes have been reported to interact via P2Y receptors^{14,16}. Although activated macrophages have also been reported to attract astrocytes¹⁷, the detailed mechanisms through which this occurs remain unclear. In the present study, focusing on P2Y₁R, which is expressed in various cells in the CNS, we showed that macrophages significantly affect astrocyte migration, which may occur during the acute to subacute phase, via P2Y₁R. While the reduction of macrophages decreases astrocyte scarring¹⁸, macrophages have also been reported to promote tissue repair¹⁹. In SCI, macrophages may have a dual role, not only scarring astrocytes via inflammatory cytokines but also attracting astrocytes, and reducing the extent of the scar. Since macrophages comprise the majority of inflammatory cells in the spinal cord scar and astrocytes are the major component of the glial scar, clarifying the interaction between macrophages and astrocytes is essential for elucidating the pathophysiology of SCI.

Although this study showed that macrophages may regulate astrocyte migration as one of the stages in glial scar formation, we have no clear evidence as to whether macrophages are involved in other stages, particularly the change from reactive astrocytes to scar-forming astrocytes. However, it is possible that macrophages may be involved in scarring by secreting collagen or by changing the composition of the extracellular matrix. We have reported that type I collagen triggers the change from reactive astrocytes to scar-forming astrocytes²⁰. Macrophages may also contribute to astrocytic scarring because macrophages are known to secrete collagen²¹ and affect the composition of the extracellular matrix by affecting other cells, such as fibroblasts²².

In addition, given that the glial scar, once formed in the subacute phase, is maintained into the chronic phase, the macrophage-derived ADP-astrocytic P2Y₁R axis may also be involved in the mechanisms of glial scar maintenance²³. We previously reported that scar-forming astrocytes maintain the glial scar by changing the surrounding naïve astrocytes to scar-forming astrocytes²³. However, it is not known how astrocytes are recruited to the scar. It has already been reported that astrocytes secrete ATP²⁴. Astrocyte-derived ATP is degraded to ADP and may attract other astrocytes. With regard to scar maintenance in the chronic phase, astrocytes may have been recruited to scar tissue via the macrophage- or astrocyte-derived ADP-astrocyte P2Y₁R axis.

To date, there have been many reports regarding whether astrocytes migrate after CNS injury. Bardehle et al. reported that GLAST⁺ astrocytes did not migrate. However, there are many different populations of astrocytes²⁵. Thus, Nestin⁺ astrocytes, which we defined as reactive astrocytes, and GLAST⁺ astrocytes may be different populations. The difference in the injury models adopted also has a major effect. In the contusion injury model we adopted, the injury area is larger than in the stab injury model, which results in the formation of an astrocyte-deficient space at the center of the injury. This space is filled by astrocytes over time. It is unlikely that this occurs without the migration of astrocytes. Furthermore, Tsai et al. reported that astrocytes are unlikely to migrate outside the originally defined region in the axial direction. However, we showed that labeled astrocytes or transplanted astrocytes migrated in the craniocaudal direction after SCI^{4,20}. Therefore, although further discussion and experimentation are needed, in our spinal cord contusion injury model, astrocytes may migrate in a sagittal direction toward the center of injury.

In this study, we showed a mechanism in which macrophages attract astrocytes to the center of injury. Considering that astrocytes are arranged in a row at the outer edge of the scar and are rarely present inside the glial scar, astrocyte migration is not regulated only by the concentration gradient of ADP; some factor inside the scar stops astrocyte migration. However, the mechanism that stops the migration of astrocytes at the glial scar has not been elucidated. For example, PARP1 may be a candidate for the negative regulation of astrocyte migration. Stat3 is known to be essential for astrocyte migration⁴, and PARP1 has been reported to interact directly inhibit Stat3 phosphorylation by causing poly-ADP-ribosylation of Stat3²⁶. The expression of PARP1 was upregulated in the spinal cord after SCI in comparison to the naïve spinal cord, as was previously shown in our RNA-seq study²⁰. This result is consistent with the hypothesis that PARP1 negatively regulates astrocyte migration in SCI.

In conclusion, we demonstrated that the impairment of macrophage migration led to widespread astrocyte distribution. Macrophages secrete ATP that is degraded to ADP, and astrocytes migrate toward macrophages via the ADP-P2Y₁R pathway. Our findings provide deeper insight into the interaction between astrocytes and macrophages and suggest a potential therapeutic target for SCI.

Methods

Animals. All study protocols involving mice were approved by the Committee of Ethics on Animal Experimentation of our institution and were conducted in accordance with ARRIVE guidelines (<https://arriveguidelines.org>) and with the National Institutes of Health guidelines for the care and use of animals. All mice were

housed in a temperature and humidity-controlled environment on a 12-h light–dark cycle and had ad libitum access to food and water. *IRF8*^{−/−}, *Nes-EGFP*⁺, and *Nes-EGFP*⁺–*Socs3*^{−/−} mice were generated as described previously^{4,27}. Bone marrow transplantation was performed as previously described²⁸. Eight-week-old female C57BL/6J mice were used as WT mice. Macrophage IRF8-deficient chimeric mice were generated by transferring the bone marrow cells (BMCs) of *IRF8*^{−/−} mice into *Nes-EGFP*⁺ and *Nes-EGFP*⁺–*Socs3*^{−/−} recipient mice after irradiation, as previously described²⁸.

Spinal cord injury. Mice were anesthetized with pentobarbital (75 mg/kg intraperitoneally) and subjected to a contusion injury (70 kilodynes) at the 10th thoracic level using an Infinite Horizons Impactor (Precision Systems Instrumentation, Lexington, KY)²⁹. After the injury, the overlying muscles were sutured, and the skin was closed with wound clips. During the period of recovery from anesthesia, the animals were placed in a temperature-controlled chamber until thermoregulation was re-established. Motor function was evaluated using a locomotor open-field rating scale, the BMS³⁰.

MRS-2179 injection. A glass tip was inserted at the epicenter of the injured spinal cord, and 2 µl of MRS-2179 (1 mM; Abcam, Cambridge, UK) was injected at 0.5 µl/min using a stereotaxic injector (KDS 310, Muromachi Kikai) at 4 and 7 dpi³¹. Control animals received 2 µl of PBS at 4 and 7 dpi.

Continuous intraspinal injection of ADP. At 4 dpi, an Alzet Brain Infusion Kit 3 (Alzet 8851; Alzet, USA) was inserted 1.5 mm from the dura mater at the epicenter of the injured spinal cord. An osmotic pump (Alzet 1002; Alzet, USA) filled with 1 mM ADP or PBS and primed for 3 h before surgery was implanted and connected to an Alzet Brain Infusion Kit 3. ADP and PBS were administered continuously from 4 to 14 days after SCI. The delivery rate of the osmotic pump was 0.25 µl/h. ADP was dissolved in PBS and then adjusted to pH 7.4 using 1 mM NaOH.

Primary astrocyte cultures. Purified primary astrocyte cultures were prepared from C57BL/6J mice, as described previously^{4,32}. In brief, after removal of the meninges, on postnatal day 2, mouse brain tissues were minced and incubated in a rocking water bath at 37 °C for 30 min in DMEM (08456-36, Nacalai Tesque Kyoto, Japan) in the presence of 0.25% trypsin (Nacalai Tesque Kyoto, Japan) and 4 mg/ml DNase I (Sigma, Saint Louis, MO). The dissociated cells were triturated with 0.25% FBS and centrifuged at 300×g for 3 min. Following dilution with an astrocyte-specific medium: DMEM containing 10% FBS (Life Technologies, Carlsbad, CA) and 1% penicillin–streptomycin (Nacalai Tesque Kyoto, Japan), the cells were plated on a poly-L-lysine-coated T75 flask. After 7 days in a humidified CO₂ incubator at 37 °C, the T75 flask was set up on an orbital shaker to remove microglia at 180 rpm for 30 min. We added 20 ml of fresh astrocyte culture medium and then shook the flask at 240 rpm for 6 h to remove oligodendrocyte precursor cells. Astrocytes were detached from T75 flasks using 0.25% trypsin and were used for experiments on that day.

Primary macrophage culture. Purified primary macrophage cultures were prepared from C57BL/6J mice, as described previously³³. In brief, after removing the muscles and tendons, bone marrow cells were extracted from the femur. Following dilution with macrophage differentiation-specific medium, RPMI 1640 (Nacalai Tesque Kyoto, Japan) containing 10% FBS (Life Technologies, Carlsbad, CA), 1% penicillin–streptomycin (Nacalai Tesque Kyoto, Japan), and 40 ng/ml M-CSF (RSD, Minneapolis, MN 55413), the cells were plated in a poly-L-Lysine-coated T25 flask. After 6 days in a humidified CO₂ incubator at 37 °C, the macrophages were detached from the T25 flask using EDTA (Nacalai Tesque Kyoto, Japan).

Quantitative reverse transcription polymerase chain reaction (RT–PCR). Total RNA was isolated from the astrocytes obtained from spinal cord tissue using the RNeasy Mini kit (Qiagen, Venlo, the Netherlands). cDNA was synthesized from the total RNA using PrimeScript Reverse Transcriptase (Takara, Tokyo, Japan) according to the manufacturer’s instructions. RT–qPCR was performed using primers specific to the genes of interest (Table 1) and a SYBR Premix Dimmer-Eraser (RR091A; Takara Bio, Shiga, Japan). Data were normalized to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Real-time PCR was conducted using a CFX Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA).

Histopathological examinations. After animals were anesthetized and transcardially fixed with 4% paraformaldehyde (PFA; Millipore, Burlington, MA), the spinal cord from T7 to T11 was removed, dehydrated, and embedded in an optimal cutting temperature compound (Sakura Finetek Japan, Tokyo, Japan). The sections were mounted on MAS-coated slide glasses (Matsunami Glass, Kishiwada, Japan). Astrocytes cultured in vitro were washed three times with PBS and fixed for 15 min in 4% PFA at room temperature. After washing three

Gene symbol	Accession number	5'-Forward primer-3'	5'-Reverse Primer-3'
<i>Slc39a6</i>	NM_031168.2	TGAAGGCAGCAGCAATAGCA	GGCCTGGATGGTGATCATG
<i>Gapdh</i>	NM_008084.2	GACTTCAACAGCAACTCCCACTCT	GGTTTCTTACTCCTTGGAGGCCAT

Table 1. Primers used for quantitative RT–PCR.

times with PBS, these sections and cells were used for immunofluorescence staining. Then, the sections were stained with the following antibodies in a blocking solution overnight at 4 °C: GFAP (1:500; rabbit; Dako, Santa Clara, CA; Z0334), GFAP (1:500; rat; Life Technologies, Carlsbad, CA; 130300), CD68 (1:1000; rat; Bio Rad, Hercules, CA; 94547), and P2Y1R (1:500; rabbit; Allomone Labs, Jerusalem, ISR; APR-021). The primary antibodies were visualized with secondary antibodies conjugated to Alexa 488, 568, 647 (1:1000; Jackson ImmunoResearch, West Grove, PA). The nuclei were visualized with Hoechst 33258 (1:1000; Invitrogen, Waltham, MA). Figures 1b, 2b,g,h and 3c,d were evaluated at the center of injury in 1 section per animal (n = 6). Figure 5b,e,g and Supplementary Fig. S1b were evaluated at the center of injury in 2 sections per animal (n = 6). The area of EGFP⁺ reactive astrocytes in Fig. 2g,h was measured for 20 cells that were randomly extracted from these sections. All images were captured using a BZ-X700 digital microscope system (Keyence, Osaka, Japan).

Transwell assay. The transwell assay was performed as described previously³⁴. Using transwell inserts (No 354480; Corning; NY; 14831), a transwell assay was performed in 5 groups: (1) the control group: primary astrocytes in the inserts, with RPMI 1640 in the well; (2) the macrophage group: primary astrocytes in the inserts, with RPMI 1640 with primary macrophages in the well; (3) the ADP group: primary astrocytes in the inserts, with RPMI 1640 with ADP (100 µM; Oriental Yeast, Tokyo, Japan) in the well; (4) the apyrase group: primary astrocytes in the inserts, with RPMI 1640 with primary macrophages and apyrase (10 U/ml; Sigma, Saint Louis, MO) in the well; and (5) the MRS-2179 group: primary astrocytes treated with MRS-2179 (10 µM; Abcam, Cambridge, UK) in the inserts, with RPMI 1640 with primary macrophages in the well. Each insert was seeded with 5.0×10^4 cells of astrocytes and each well was seeded with 5.0×10^4 cells of macrophages. After incubation for 24 h and staining with Diff-Quick (Sysmex, Kobe, Japan), the number of migrating cells was counted in 9 sections/3 wells per group. The percentage increase in migrating cells compared to the control group was evaluated.

Statistical analyses. All statistical analyses were performed using the GraphPad Prism software program, version 9.1.2 (GraphPad Software Inc., San Diego, CA.). Figures 2b,g,h, 4d, 5b,e,g and Supplementary Fig. S1b were subjected to an unpaired *t*-test, while Figs. 3c,d and 4g were subjected to an ordinary one-way ANOVA. Figure 3e was subjected to a two-way ANOVA.

Ethics approval. Ethical approval was obtained from the ethical review committee of Kyushu University Graduate School of Medical Sciences (A25-089-0/A22-336-1) in accordance with the provisions of the institution's Regulation for Animal Experiments.

Data availability

The datasets generated and/or analyzed in the current study are available upon request from the corresponding author.

Received: 30 December 2022; Accepted: 6 July 2023

Published online: 10 July 2023

References

- McDonald, J. W. & Sadowsky, C. Spinal-cord injury. *Lancet* **359**, 417–425 (2002).
- Anjum, A. *et al.* Molecular sciences spinal cord injury: Pathophysiology, multimolecular interactions, and underlying recovery mechanisms. *Int. J. Mol. Sci.* **21**, 7533. <https://doi.org/10.3390/ijms21207533> (2020).
- Tran, A. P., Warren, P. M. & Silver, J. The biology of regeneration failure and success after spinal cord injury. *Physiol. Rev.* **98**, 881 (2018).
- Okada, S. *et al.* Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. *Nat. Med.* **12**, 829. <https://doi.org/10.1038/nm1425> (2006).
- Orr, M. B. & Gensel, J. C. Spinal cord injury scarring and inflammation: Therapies targeting glial and inflammatory responses. *Neurotherapeutics* **15**, 541 (2018).
- Kobayakawa, K. *et al.* Macrophage centripetal migration drives spontaneous healing process after spinal cord injury. *Sci. Adv.* **5**, 5086 (2019).
- Illes, P., Xu, G.-Y. & Tang, Y. Purinergic signaling in the central nervous system in health and disease. *Neurosci. Bull.* **36**, 1239 (2020).
- Burnstock, G. Introduction to purinergic signalling in the brain. *Adv. Exp. Med. Biol.* **1202**, 1–12 (2020).
- Kronlage, M. *et al.* Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. *Sci. Signal.* **3**, 588 (2010).
- Ceyzeriat, K., Abjean, L., Carrillo-de Sauvage, M. A., Ben Haim, L. & Escartin, C. The complex STATs of astrocyte reactivity: How are they controlled by the JAK–STAT3 pathway? *Neuroscience* **330**, 205–218 (2016).
- Renault-Mihara, F. & Okano, H. STAT3-regulated RhoA drives reactive astrocyte dynamics. *Cell Cycle* **16**, 1995–1996 (2017).
- Gao, Q. *et al.* Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 4661 (2004).
- Mori, H. *et al.* Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. *Nat. Med.* **10**, 739–743 (2004).
- Shinozaki, Y., Shibata, K., Ikenaka, K., Tanaka, K. F. & Correspondence, S. K. Transformation of astrocytes to a neuroprotective phenotype by microglia via P2Y1 receptor downregulation. *Cell Rep.* **19**, 1151 (2017).
- Shen, J. & Dicorleto, P. E. ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways. *Circ. Res.* **102**, 448. <https://doi.org/10.1161/CIRCRESAHA.107.165795> (2008).
- Kofuji, P. & Araque, A. G-protein-coupled receptors in astrocyte–neuron communication. *Neuroscience* **456**, 71 (2021).
- Fitch, M. T., Doller, C., Combs, C. K., Landreth, G. E. & Silver, J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: In vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. *J. Neurosci.* **19**, 8182 (1999).
- Frik, J. *et al.* Cross-talk between monocyte invasion and astrocyte proliferation regulates scarring in brain injury. *EMBO Rep.* **19**, 294 (2018).

19. Milich, L. M., Ryan, C. B. & Lee, J. K. The origin, fate, and contribution of macrophages to spinal cord injury pathology. *Acta Neuropathol.* **137**, 785 (2019).
20. Hara, M. *et al.* Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin–N-cadherin pathway after spinal cord injury. *Nat. Med.* **23**, 818–828 (2017).
21. Schnoor, M. *et al.* Production of type VI collagen by human macrophages: A new dimension in macrophage functional heterogeneity. *J. Immunol.* **180**, 5707–5719 (2008).
22. Simões, F. C. *et al.* Macrophages directly contribute collagen to scar formation during zebrafish heart regeneration and mouse heart repair. *Nat. Commun.* **11**, 2 (2020).
23. Tamaru, T. *et al.* Glial scar survives until the chronic phase by recruiting scar-forming astrocytes after spinal cord injury. *Exp. Neurol.* **359**, 114264 (2023).
24. Coco, S. *et al.* Storage and release of ATP from astrocytes in culture. *J. Biol. Chem.* **278**, 1354–1362 (2003).
25. Clavreul, S., Dumas, L. & Loulier, K. Astrocyte development in the cerebral cortex: Complexity of their origin, genesis, and maturation. *Front. Neurosci.* **16**, 916055 (2022).
26. Ding, L. *et al.* PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3. *Cancer Immunol. Res.* **7**, 136–149 (2019).
27. Holtschke, T. *et al.* Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* **87**, 307–317 (1996).
28. Rolls, A. *et al.* Two faces of chondroitin sulfate proteoglycan in spinal cord repair: A role in microglia/macrophage activation. *PLoS Med.* **5**, e171 (2008).
29. Kobayakawa, K. *et al.* Acute hyperglycemia impairs functional improvement after spinal cord injury in mice and humans. *Sci. Transl. Med.* **6**, 9430 (2014).
30. Ma, M., Basso, D. M., Walters, P., Stokes, B. T. & Jakeman, L. B. Behavioral and histological outcomes following graded spinal cord contusion injury in the C57Bl/6 mouse. *Exp. Neurol.* **169**, 239–254 (2001).
31. Kumamaru, H. *et al.* Direct isolation and RNA-seq reveal environment-dependent properties of engrafted neural stem/progenitor cells. *Nat. Commun.* **3**, 2132 (2012).
32. Schildge, S., Bohrer, C., Beck, K. & Schachtrup, C. Isolation and culture of mouse cortical astrocytes. *J. Vis. Exp.* <https://doi.org/10.3791/50079> (2013).
33. Ying, W., Cheruku, P. S., Bazer, F. W., Safe, S. H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. *J. Vis. Exp.* <https://doi.org/10.3791/50323> (2013).
34. Marshall, J. Transwell(®) invasion assays. *Methods Mol. Biol.* **769**, 97–110 (2011).

Acknowledgements

The authors appreciate the technical assistance from The Research Support Center, Research Center for Human Disease Modeling, Kyushu University Graduate School of Medical Sciences.

Author contributions

G.O. and K.Kobayakawa performed the experiments and analyzed the data. H.S. and K.Kobayakawa supervised the design of the research. H.I., T.Tamaru, Y.H., K.Kitade, K.Iida, K.Kawaguchi, Y.M. and Y.N. contributed equally to the work. T.M. and D.K. provided guidance on experimental technology. M.T., T.Tamura, K.O. and K.Inoue provided *IRF8*^{−/−} mice. G.O. wrote the original draft. H.S. and K.Kobayakawa reviewed and edited the manuscript. All authors read and approved the final manuscript. All listed authors consented to the submission of this manuscript, and all data were used with the consent of the individual who generated the data.

Funding

This study was supported by JSPS KAKENHI Grant Numbers (JP18K16665, JP19K18515, JP22K09426, JP22K19587 and 23H03031), JST FOREST Program (JPMJFR220P), ZENKYOREN (National Mutual Insurance Federation of Agricultural Cooperatives), Takeda Science Foundation and The General Insurance Association of Japan.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-38301-8>.

Correspondence and requests for materials should be addressed to K.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023